[go: up one dir, main page]

SI3658147T1 - Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka - Google Patents

Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka

Info

Publication number
SI3658147T1
SI3658147T1 SI201830528T SI201830528T SI3658147T1 SI 3658147 T1 SI3658147 T1 SI 3658147T1 SI 201830528 T SI201830528 T SI 201830528T SI 201830528 T SI201830528 T SI 201830528T SI 3658147 T1 SI3658147 T1 SI 3658147T1
Authority
SI
Slovenia
Prior art keywords
annulene
palbociclib
oxyphenyl
fluoropropyl
pyrrolidin
Prior art date
Application number
SI201830528T
Other languages
English (en)
Inventor
Monsif Bouaboula
Maysoun Shomali
Fangxian Sun
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of SI3658147T1 publication Critical patent/SI3658147T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201830528T 2017-07-24 2018-07-23 Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka SI3658147T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762536121P 2017-07-24 2017-07-24
EP17305998.1A EP3434272A1 (en) 2017-07-25 2017-07-25 Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
EP18740615.2A EP3658147B1 (en) 2017-07-24 2018-07-23 Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid and its use for the treatment of cancer
PCT/EP2018/069901 WO2019020559A1 (en) 2017-07-24 2018-07-23 COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
SI3658147T1 true SI3658147T1 (sl) 2022-02-28

Family

ID=59569252

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830528T SI3658147T1 (sl) 2017-07-24 2018-07-23 Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka

Country Status (30)

Country Link
US (2) US11260057B2 (sl)
EP (2) EP3434272A1 (sl)
JP (1) JP6741897B1 (sl)
KR (1) KR20200031622A (sl)
CN (1) CN111107851B (sl)
AR (1) AR112284A1 (sl)
AU (1) AU2018308871A1 (sl)
BR (1) BR112020001398A2 (sl)
CA (1) CA3070754A1 (sl)
CO (1) CO2020000240A2 (sl)
DK (1) DK3658147T3 (sl)
ES (1) ES2906279T3 (sl)
HR (1) HRP20212030T1 (sl)
HU (1) HUE057271T2 (sl)
IL (1) IL272166B2 (sl)
LT (1) LT3658147T (sl)
MA (1) MA49673B1 (sl)
MX (1) MX393852B (sl)
MY (1) MY195271A (sl)
PH (1) PH12020500091A1 (sl)
PL (1) PL3658147T3 (sl)
PT (1) PT3658147T (sl)
RS (1) RS62837B1 (sl)
RU (1) RU2764116C2 (sl)
SG (1) SG11202000367RA (sl)
SI (1) SI3658147T1 (sl)
TW (1) TWI768087B (sl)
UY (1) UY37818A (sl)
WO (1) WO2019020559A1 (sl)
ZA (1) ZA202000145B (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2019335542A1 (en) 2018-09-07 2021-04-01 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate
BR112021022216A2 (pt) * 2019-05-09 2021-12-28 Sanofi Sa Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
KR20220113695A (ko) * 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
JP2023550149A (ja) * 2020-11-23 2023-11-30 サノフイ アベマシクリブと６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸とを含む組み合わせ
TW202302084A (zh) * 2021-03-02 2023-01-16 法商賽諾菲公司 以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR102815360B1 (ko) 2022-03-03 2025-06-02 인하대학교 산학협력단 암의 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE60108354T2 (de) 2001-01-24 2006-01-05 Chiesi Farmaceutici S.P.A. 2H-1-Benzopyranderivate, Verfahren zu ihrer Herstellung und deren pharmazeutische Zusammensetzungen
JP2005528320A (ja) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 選択的なエストロゲン受容体モジュレーター
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
BRPI0512623A (pt) 2004-06-25 2008-03-25 Janssen Phamaceutica N V sal quaternário antagonista de ccr2
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
ES2586908T3 (es) 2010-12-24 2016-10-19 Merck Sharp & Dohme B.V. Derivados de azetidina N-sustituidos
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2015504049A (ja) 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドＣｅｎｔａｕｒｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
MX378263B (es) * 2013-08-14 2025-03-10 Novartis Ag Terapia de combinación para el tratamiento del cáncer.
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
NZ769496A (en) 2014-12-18 2023-09-29 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3288383A4 (en) * 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
CN106924210A (zh) * 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
PE20181893A1 (es) * 2016-02-15 2018-12-11 Sanofi Sa Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos
JP6946430B2 (ja) 2016-11-17 2021-10-06 サノフイＳａｎｏｆｉ 新規の置換ｎ−（３−フルオロプロピル）−ピロリジン化合物、それを製造するための方法、およびその治療的使用
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2019335542A1 (en) 2018-09-07 2021-04-01 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate
JP2022507495A (ja) * 2018-11-16 2022-01-18 アーキュール・インコーポレイテッド 癌治療のための医薬の組合せ

Also Published As

Publication number Publication date
AR112284A1 (es) 2019-10-09
JP6741897B1 (ja) 2020-08-19
AU2018308871A1 (en) 2020-02-06
CN111107851A (zh) 2020-05-05
PT3658147T (pt) 2022-02-02
CN111107851B (zh) 2023-05-12
UY37818A (es) 2020-08-31
WO2019020559A1 (en) 2019-01-31
RU2020107416A3 (sl) 2021-08-25
MA49673B1 (fr) 2022-02-28
ZA202000145B (en) 2021-07-28
US11260057B2 (en) 2022-03-01
JP2020526572A (ja) 2020-08-31
TW201919612A (zh) 2019-06-01
RU2020107416A (ru) 2021-08-25
MY195271A (en) 2023-01-11
US20220362248A1 (en) 2022-11-17
KR20200031622A (ko) 2020-03-24
IL272166B (en) 2022-12-01
EP3658147A1 (en) 2020-06-03
SG11202000367RA (en) 2020-02-27
EP3434272A1 (en) 2019-01-30
BR112020001398A2 (pt) 2020-07-28
RU2764116C2 (ru) 2022-01-13
TWI768087B (zh) 2022-06-21
MX393852B (es) 2025-03-24
US20200171033A1 (en) 2020-06-04
HUE057271T2 (hu) 2022-04-28
IL272166A (en) 2020-03-31
RS62837B1 (sr) 2022-02-28
EP3658147B1 (en) 2021-11-10
MA49673A (fr) 2021-03-24
PH12020500091A1 (en) 2020-09-14
IL272166B2 (en) 2023-04-01
DK3658147T3 (da) 2022-01-31
CA3070754A1 (en) 2019-01-31
LT3658147T (lt) 2022-01-10
PL3658147T3 (pl) 2022-03-07
CO2020000240A2 (es) 2020-04-24
ES2906279T3 (es) 2022-04-18
HRP20212030T1 (hr) 2022-04-01

Similar Documents

Publication Publication Date Title
SI3658147T1 (sl) Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka
PH12020500171A1 (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP4233910A3 (en) Methods of treatment of cholestatic diseases
CR20200274A (es) Oxadiazoles fungicidas
GB2552063B (en) Medical scope accessory, medical scopes comprising the accessory, and use thereof
MX2018015247A (es) Heterociclos de biarilmetilo.
IL276326A (en) Dihydropyrimidinone or dihydrotriazinone compounds with a saturated compressed ring and their pharmaceutical use
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
DK3456712T3 (da) Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
LT3408260T (lt) Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
IL268549B (en) 1-(4-amino-5-bromo-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol and its use in cancer treatment
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis
HK40019959A (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
EP3646872A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
IL266099B (en) N-((4r,3s)-1-(8-chloroquinoxaline-6-yl)carbonyl)-3-(4-fluorophenyl)-piperidine-4-yl)-1-methyl-5-(trifluoromethyl)-1h- Pyrazole-3-carboxamide and its medical use
HK40010513A (en) 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
HK40027519A (en) Low-alcohol and sterilizable antimicrobial compositions and use thereof